Benjamin Hohl Insider Trades & Stock Holdings

CHIEF FINANCIAL OFFICER · Enliven Therapeutics, Inc. · Latest filing Oct 19, 2026

Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. has 3 Form 4 trades on file since Jul 17, 2026. Open-market activity: 0 purchases ($0) and 3 sales ($851.33K), net -$851.33K. Latest filing: disposed of 6.02K shares of $ELVN on Oct 19, 2026 at $38.48.

Trades on file

3

Open-market bought

$0

Open-market sold

$851.33K

Net open-market

-$851.33K

Shares held ($ELVN)

38K

Latest filing

Oct 19, 2026

Shares held by Benjamin Hohl

• $ELVN38K sh

Shares owned after the most recent Form 4 for each company.

All insider trades by Benjamin Hohl

Date	Ticker	Type	Shares	Price	Value	Owned after	ΔOwn	1W	1M	6M	Role	Filing	Story
Oct 19, 2026	$ELVN	Sell (Open-market sale) 10b5-1	6.02K	$38.48	$231.55K	38K	-13.67%				CHIEF FINANCIAL OFFICER	SEC	Read
Sep 17, 2026	$ELVN	Sell (Open-market sale) 10b5-1	6.02K	$50.35	$303K	38K	-13.67%	-10.1%	-23.0%		CHIEF FINANCIAL OFFICER	SEC	—
Jul 17, 2026	$ELVN	Sell (Open-market sale) 10b5-1	6.02K	$52.64	$316.78K	46.05K	-11.56%	-0.5%	+11.9%		CHIEF FINANCIAL OFFICER	SEC	—

"Buy" means shares acquired on the Form 4 (including grants and option exercises); "Sell" means shares disposed. 1W / 1M / 6M = how the stock moved after the trade.

Stocks Benjamin Hohl traded

• $ELVN

Frequently asked questions

Has Benjamin Hohl been buying or selling stock?

Benjamin Hohl has 0 open-market purchases and 3 open-market sales on file, net -$851.33K. Grants, option exercises and tax withholding are listed separately because they are not open-market trades.

What was Benjamin Hohl's latest insider trade?

disposed of 6.02K shares of $ELVN on Oct 19, 2026 at $38.48.

Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.